Cabazitaxel is a semi-synthetic derivative of a natural taxoid.
Hey next generation taxane
For the treatment of hormone-refractory prostate cancer.
Trade name Jevtana.
A microtubule inhibitor.
In combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.
Retains activity in patients whose disease progressed while receiving docetaxel or androgen signaling-targeted inhibitors.
Has a lower incidence of alopecia, peripheral neuropathy, peripheral edema, and nail disorders.
In a phase III trial with 755 men for the treatment of hormone-refractory prostate cancer, median survival was 15.1 months for patients receiving cabazitaxel versus 12.7 months for patients receiving mitoxantrone, and a 30% reduced risk of death compared to mitoxantrone.
Cabazitaxel is associated with neutropenia.
Most common adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.
Increases median survival by 2.4 months when compared with mitoxanthone.
Administered as a one hour infusion every three weeks with concomitant steroid use.
Primary safety considerations are myelosuppression.
Similar survival of 20mg/m2 vs 25 mg/m2.
Compared with abiraterone or enzalutamide, cabazitaxel significantly improved clinical outcomes in patients with metastatic castration-resistant prostate cancer who previously received docetaxel plus abiraterone or enzalutamide.
Randomized 255 patients previously treated with docetaxel and abiraterone or enzalutamide to receive cabazitaxel 25 mg/m2 intravenously every 3 weeks plus prednisone daily and granulocyte colony-stimulating factor or either 1000 mg of abiraterone plus prednisone or 160 mg of enzalutamide daily.
The primary end point of the study was progression-free survival (PFS), and secondary end points included survival, response, and safety.
Follow-up lasted for a median of 9.2 months, at which point imaging-based progression or death was reported in 95 (73.6%) and 101 (80.2%) patients in the cabazitaxel and noncabazitaxel arms, respectively.
The median imaging-based PFS was 8.0 and 3.7 months, respectively.
The median rate of overall survival was 13.6 months in the cabazitaxel arm versus 11.0 months in the noncabazitaxel arm.
The median PFS was 4.4 months and 2.7 months, respectively.
A prostate-specific antigen response was observed in 35.7% and 13.5% of patients, respectively.
In addition, tumor response was noted in 36.5% and 11.5% of patients.
Cabazitaxel significantly improved a number of clinical outcomes, as compared with abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone or enzalutamide.